Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

被引：1
|
作者：
Beauverd, Yan [1 ]
McLornan, Donal P. [1 ,2 ]
Radia, Deepti H. [1 ]
Harrison, Claire N. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Hematol, London, England
[2] Kings Coll Hosp NHS Fdn Trust, Dept Hematol Med, London, England
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 06期
关键词：
myeloproliferative neoplasms; outcomes; polycythemia vera; ruxolitinib; treatment; ESSENTIAL THROMBOCYTHEMIA; JAK INHIBITION; PRIMARY MYELOFIBROSIS; CELL-FUNCTION; LOW TOXICITY; HYDROXYUREA; SAFETY; HYDROXYCARBAMIDE; PHARMACOKINETICS; INTOLERANCE;
D O I：
10.2217/fon-2015-0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.
引用
收藏
页码：739 / 749
页数：11
相关论文
共 50 条
  • [31] The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis
    Samuelson, Bethany T.
    Vesely, Sara K.
    Chai-Adisaksopha, Chatree
    Scott, Bart L.
    Crowther, Mark
    Garcia, David
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (06) : 648 - 652
  • [32] SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM THE CLINICAL TRIAL PROGRAM
    Verstovsek, S.
    Mesa, R.
    Martino, B.
    Kiladjian, J. -J.
    Jones, M. M.
    He, S.
    Habr, D.
    Alecu, I.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 263 - 264
  • [33] Real-World Outcomes of Ruxolitinib for Polycythemia Vera
    Coltoff, Alexander
    Tremblay, Douglas
    Kremyanskaya, Marina
    Hoffman, Ronald
    Mascarenhas, John
    BLOOD, 2017, 130
  • [34] The Efficacy of Anticoagulant Treatment on the Evolution of Thrombotic Complications in Patients With Polycythemia Vera Syndrome
    Badulescu, O.
    Badescu, C.
    Ciocoiu, M.
    Badescu, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S642 - S642
  • [35] EVOLUTION INTO AND TREATMENT OF LATE STAGE POLYCYTHEMIA-VERA
    SILVERSTEIN, MN
    SEMINARS IN HEMATOLOGY, 1976, 13 (01) : 79 - 84
  • [36] Safety and efficacy of long-term ruxolitinib treatment in 25 high-risk polycythemia vera patients
    Sadjadian, P.
    Becker, T.
    Wille, K.
    Griesshammer, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 149 - 149
  • [37] RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: IS THERE A DIFFERENCE IN RESPONSES BETWEEN INTOLERANT AND HYDROXYUREA RESISTANT-PATIENTS?
    Gonzalez Perez, E.
    Saez Perdomo, M. N.
    Fernandez Fuertes, F.
    Raya Sanchez, J. M.
    Mayani, K.
    Tapia Torres, M.
    Segura Diaz, A.
    Sanchez Sosa, S.
    Florido Ortega, Y.
    Bilbao Sieyro, C.
    Stuckey, R.
    Molero Labarta, M. T.
    Gomez Casares, M. T.
    HAEMATOLOGICA, 2019, 104 : 309 - 310
  • [38] Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy
    Verstovsek, Srdan
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Miller, Carole
    Naim, Ahmad B.
    Paranagama, Dilan C.
    Habr, Dany
    Vannucchi, Alessandro M.
    LEUKEMIA RESEARCH, 2017, 56 : 52 - 59
  • [39] Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    Jones, Mark M.
    He, Shui
    Li, Jingjin
    Habr, Dany
    Kiladjian, Jean-Jacques
    BLOOD, 2014, 124 (21)
  • [40] Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
    Chojecki, Aleksander
    Boselli, Danielle
    Dortilus, Allison
    Hamadeh, Issam
    Begley, Stephanie
    Chen, Tommy
    Bose, Rupali
    Podoltsev, Nikolai
    Zeidan, Amer M.
    Balmaceda, Nicole Baranda
    Yacoub, Abdulraheem
    Ai, Jing
    Knight, Thomas Gregory
    Ragon, Brittany Knick
    Shah, Nilay Arvind
    Sanikommu, Srinivasa Reddy
    Symanowski, James
    Mesa, Ruben
    Grunwald, Michael Richard
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 2837 - 2843
12345